NO20054892L - Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon - Google Patents

Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon

Info

Publication number
NO20054892L
NO20054892L NO20054892A NO20054892A NO20054892L NO 20054892 L NO20054892 L NO 20054892L NO 20054892 A NO20054892 A NO 20054892A NO 20054892 A NO20054892 A NO 20054892A NO 20054892 L NO20054892 L NO 20054892L
Authority
NO
Norway
Prior art keywords
antibodies
binding partners
methods
inflammation
antagonizing
Prior art date
Application number
NO20054892A
Other languages
English (en)
Other versions
NO20054892D0 (no
Inventor
Anthony W Siadak
Wenfeng Xu
Wayne Kindsvogel
Yasmin Chandraksekher
Stacey R Dillion
Joyce M Lehner
Pallavur V Sivakumar
Margaret S Moore
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33101289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054892(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of NO20054892D0 publication Critical patent/NO20054892D0/no
Publication of NO20054892L publication Critical patent/NO20054892L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Sammendrag Foreliggende oppfinnelse vedrører blokkering, inhibering, redusering, antagonisering eller nøytralisering av aktiviteten til IL-22, IL-20 eller både IL-20- og IL-22-polypeptid molekyler. IL-20 og IL22 er cytokiner som er involvert i inflammatoriske prosesser og human sykdom. IL-22RA (zcytorl 1) er en vanlig reseptor for IL-20 og IL-22. Foreliggende oppfinnelse inkluderer anti-IL-22RA-antistoffer og bindingspartnere i tillegg til fremgangsmåter for å antagonisere IL-22 eller både IL-20 og IL-22 ved å benytte slike antistoffer og bindingspartnere.
NO20054892A 2003-03-24 2005-10-21 Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon NO20054892L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45748103P 2003-03-24 2003-03-24
US52329503P 2003-11-17 2003-11-17
PCT/US2004/008956 WO2004085476A2 (en) 2003-03-24 2004-03-24 Anti-il-22ra antibodies and binding partners and methods of using in inflammation

Publications (2)

Publication Number Publication Date
NO20054892D0 NO20054892D0 (no) 2005-10-21
NO20054892L true NO20054892L (no) 2005-12-23

Family

ID=33101289

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054892A NO20054892L (no) 2003-03-24 2005-10-21 Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon

Country Status (16)

Country Link
US (6) US20040209330A1 (no)
EP (2) EP1606316A2 (no)
JP (2) JP2007525437A (no)
KR (3) KR20110091598A (no)
CN (2) CN102690350A (no)
AT (1) ATE475673T1 (no)
AU (2) AU2004223837C1 (no)
BR (2) BRPI0408683A (no)
CA (2) CA2519089C (no)
DE (1) DE602004028347D1 (no)
DK (1) DK1606317T3 (no)
EA (2) EA009026B1 (no)
ES (1) ES2347657T3 (no)
MX (2) MXPA05010134A (no)
NO (1) NO20054892L (no)
WO (2) WO2004085476A2 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
DE60123998T2 (de) 2000-08-08 2007-09-06 Zymogenetics, Inc., Seattle Lösliche zcyctor 11 cytokinrezeptoren
ATE460429T1 (de) 2000-09-15 2010-03-15 Zymogenetics Inc Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb
EP1531843B1 (en) 2001-12-17 2011-08-24 ZymoGenetics, Inc. Method for treating cervical cancer
KR20110091598A (ko) 2003-03-24 2011-08-11 지모제넥틱스, 인코포레이티드 항-ｉｌ-22ｒａ 항체 및 결합 파트너 및 염증에 있어서의 사용 방법
JP4991307B2 (ja) * 2003-11-21 2012-08-01 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２０抗体および結合パートナーならびに炎症において用いる方法
KR20070073863A (ko) * 2004-10-04 2007-07-10 트리니티 바이오시스템스, 인크. 거대분자의 무침 전달을 위한 방법 및 조성물
UA96122C2 (ru) 2004-10-22 2011-10-10 Займодженетикс, Инк Антитело или его антигенсвязующий фрагмент, которое специфически связывается с il-22ra, и его применение
CN100515491C (zh) * 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
US20060177447A1 (en) * 2005-02-08 2006-08-10 Wenfeng Xu Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP1954719A2 (en) * 2005-12-02 2008-08-13 Genentech Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
WO2007067597A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
WO2007067596A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
CN101341170B (zh) * 2005-12-22 2013-02-13 健能隆医药技术（上海）有限公司 抗白介素-22结合蛋白的抗体及其用途
CA2647168A1 (en) * 2006-03-16 2007-09-27 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
EP2047863B1 (en) 2006-06-08 2013-07-31 Chugai Seiyaku Kabushiki Kaisha Preventive or remedy for inflammatory disease
US20090092660A1 (en) * 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CN101874041B (zh) 2007-09-26 2013-06-19 中外制药株式会社 抗体恒定区修饰体
CN104162155A (zh) 2007-12-05 2014-11-26 中外制药株式会社 搔痒症治疗药
ES2585480T3 (es) 2007-12-05 2016-10-06 Chugai Seiyaku Kabushiki Kaisha Anticuerpo anti-NR10 y uso del mismo
DK2275443T3 (en) 2008-04-11 2016-02-08 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repetitively binding to two or more antigen molecules
WO2010000721A1 (en) 2008-06-30 2010-01-07 Novo Nordisk A/S Anti-human interleukin-20 antibodies
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
KR102385507B1 (ko) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
EP2686347B1 (en) 2011-03-16 2018-05-02 argenx BVBA Antibodies to cd70
EP2739748B1 (en) 2011-08-05 2019-04-03 Université d'Aix-Marseille Fibrosis susceptibility il22ra2 gene and uses thereof
US8597647B1 (en) * 2012-05-22 2013-12-03 National Cheng Kung University Humanized anti-IL-20 antibody and uses thereof
WO2014006230A1 (en) * 2012-07-06 2014-01-09 Novo Nordisk A/S Il-20 epitopes and il-20 ligands
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
EP2977386A1 (en) * 2012-08-31 2016-01-27 Argen-X Nv Method for producing antibody molecules having inter-species, intra-target cross-reactivity
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
RU2683020C2 (ru) * 2014-11-11 2019-03-26 Петр Иванович Никитин Субстанция и способ для модуляции активности агента в организме
BR112017022101A2 (pt) 2015-04-14 2018-07-31 Chugai Seiyaku Kabushiki Kaisha composição farmacêutica para prevenção e/ou tratamento de dermatite atópica contendo antagonista de il-31 como ingrediente ativo
CN105601739B (zh) * 2016-02-22 2019-01-18 王晨辉 一种人源化抗白介素22基因工程抗体及其应用
EP3464357A1 (en) 2016-05-24 2019-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
GB201612337D0 (en) * 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
JOP20190155A1 (ar) 2016-12-21 2019-06-23 Novartis Ag مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
WO2020210816A1 (en) * 2019-04-12 2020-10-15 Methodist Hospital Research Institute Therapeutic particles that enable antigen presenting cells to attack cancer cells
US20220307035A1 (en) * 2019-06-12 2022-09-29 Acurasysbio Co., Ltd. Composition for preventing or treating cancer
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
NZ212437A (en) * 1985-06-17 1992-06-25 Mark Philip Best Site-directed antibody conjugates, and their preparation
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5436155A (en) * 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
WO1995021258A1 (en) 1994-02-01 1995-08-10 United States Of America, Represented By The Secretary, Department Of Health And Human Services Fusion proteins that include antibody and nonantibody portions
JP3713074B2 (ja) * 1995-08-30 2005-11-02 栄研化学株式会社 血清アミロイドａを認識するモノクローナル抗体
US5843697A (en) 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
US5985614A (en) * 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6486301B1 (en) * 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
CA2296762A1 (en) 1997-07-16 1999-01-28 Human Genome Sciences, Inc. Interleukin-20
KR100236609B1 (ko) * 1997-08-01 2000-02-01 박호군 클로로하이드로실란 유도체 및 이의 제조방법
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
CA2298439A1 (en) * 1997-08-06 1999-02-18 Zymogenetics, Inc. Lipocalin homologs
US6551799B2 (en) * 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
DK1032671T3 (da) * 1997-11-26 2004-10-11 Zymogenetics Inc Mammalt cytokin-lignende polypeptid-10
CA2318482C (en) 1998-01-23 2010-04-13 Immunex Corporation Il-18 receptors
JP2002505879A (ja) 1998-03-09 2002-02-26 シェーリング コーポレイション ヒトレセプタータンパク質；関連する試薬および方法
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
US6197582B1 (en) * 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AU5203199A (en) 1998-05-26 1999-12-13 Procter & Gamble Company, The Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
CA2339043A1 (en) 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
CA2347066C (en) 1998-10-26 2011-05-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode t cell inducible factors (tifs), the proteins encoded, and uses thereof
EP1141008A1 (en) 1998-12-31 2001-10-10 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
PT1177312E (pt) 1999-04-28 2008-01-22 Genetics Inst Llc Proteínas gil-19/ae289 humanas e polinucleótidos codificadores das mesmas
EP1179066A2 (en) 1999-05-19 2002-02-13 Incyte Genomics, Inc. Extracellular signaling molecules
WO2000073457A1 (en) 1999-05-27 2000-12-07 Schering-Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
ATE448246T1 (de) 1999-06-15 2009-11-15 Genentech Inc Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
AU2883700A (en) 1999-06-23 2001-01-09 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK1860188T3 (da) 1999-07-07 2011-06-27 Zymogenetics Inc Human cytokin-receptor
CA2380355A1 (en) 1999-09-01 2001-03-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2392109A1 (en) 1999-11-18 2001-05-25 Schering Corporation Mammalian receptor proteins; related reagents and methods
ATE458814T1 (de) 1999-12-03 2010-03-15 Zymogenetics Inc Menschliches zytokinrezeptor
JP2003524415A (ja) 1999-12-23 2003-08-19 ザイモジェネティクス，インコーポレイティド サイトカインｚｃｙｔｏ１８
ATE407950T1 (de) 1999-12-23 2008-09-15 Zymogenetics Inc Löslicher interleukin-20 rezeptor
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
ATE339450T1 (de) * 1999-12-23 2006-10-15 Zymogenetics Inc Verfahren zur behandlung von entzündungen
NZ523122A (en) 2000-06-22 2004-06-25 Smithkline Beecham Corp Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
JP2002015498A (ja) * 2000-06-29 2002-01-18 Fujitsu Ltd センス電流の設定方法
DE60123998T2 (de) 2000-08-08 2007-09-06 Zymogenetics, Inc., Seattle Lösliche zcyctor 11 cytokinrezeptoren
EP1315743B1 (en) 2000-09-08 2012-11-07 Merck Sharp & Dohme Corp. Mammalian genes; related reagents and methods
ATE460429T1 (de) 2000-09-15 2010-03-15 Zymogenetics Inc Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US20030022827A1 (en) 2000-09-25 2003-01-30 Bertram Weiss Three new members of the cytokine receptor family class 2
MXPA03006218A (es) 2001-01-12 2004-09-13 Inst Genetics Llc Receptor de citosina tipo 2 y acidos nucleicos que codifican para lo mismo.
EP1390060A2 (en) 2001-01-26 2004-02-25 Eli Lilly And Company Use of lp82 to treat body weight disorders
EP1373319A2 (en) 2001-02-23 2004-01-02 Genetics Institute, LLC Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
JP2005506287A (ja) * 2001-02-28 2005-03-03 イーライ・リリー・アンド・カンパニー 造血障害を治療するためのｌｐ８２の使用
AU2002305944A1 (en) 2001-03-02 2002-09-19 Zymogenetics, Inc. Mouse cytokine receptor
AU2002245652A1 (en) * 2001-03-09 2002-09-24 Zymogenetics, Inc. Soluble heterodimeric cytokine receptor
WO2002077174A2 (en) 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
JP4414142B2 (ja) * 2001-05-11 2010-02-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 特異的結合タンパク質およびその使用
WO2003035096A1 (en) 2001-10-22 2003-05-01 Eli Lilly And Company Soluble proteins that inhibit cytokine signal transduction pathways
DE10154579A1 (de) 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
EP1531843B1 (en) 2001-12-17 2011-08-24 ZymoGenetics, Inc. Method for treating cervical cancer
US20040236075A1 (en) 2002-07-24 2004-11-25 Laure Dumoutier Novel glass II cytokine receptors, and uses thereof
KR20110091598A (ko) 2003-03-24 2011-08-11 지모제넥틱스, 인코포레이티드 항-ｉｌ-22ｒａ 항체 및 결합 파트너 및 염증에 있어서의 사용 방법
CN1845937A (zh) * 2003-03-24 2006-10-11 津莫吉尼蒂克斯公司 抗il－20抗体和结合伴侣以及在炎症中的使用方法
JP4991307B2 (ja) 2003-11-21 2012-08-01 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２０抗体および結合パートナーならびに炎症において用いる方法
UA96122C2 (ru) * 2004-10-22 2011-10-10 Займодженетикс, Инк Антитело или его антигенсвязующий фрагмент, которое специфически связывается с il-22ra, и его применение

Also Published As

Publication number Publication date
AU2004223836A1 (en) 2004-10-07
US20080233115A1 (en) 2008-09-25
CA2519057A1 (en) 2004-10-07
AU2004223837A2 (en) 2004-10-07
JP2007525437A (ja) 2007-09-06
CN103864934A (zh) 2014-06-18
EA009124B1 (ru) 2007-10-26
ES2347657T3 (es) 2010-11-03
CN102690350A (zh) 2012-09-26
BRPI0408705A (pt) 2006-03-07
EA200501505A1 (ru) 2006-06-30
WO2004085476A2 (en) 2004-10-07
ATE475673T1 (de) 2010-08-15
EP1606317A2 (en) 2005-12-21
MXPA05010136A (es) 2005-11-16
CA2519089A1 (en) 2004-10-07
AU2004223837A1 (en) 2004-10-07
EA009026B1 (ru) 2007-10-26
US8163286B2 (en) 2012-04-24
BRPI0408683A (pt) 2006-03-28
DK1606317T3 (da) 2010-10-25
CA2519089C (en) 2014-12-23
US20120207761A1 (en) 2012-08-16
US20090074661A1 (en) 2009-03-19
JP2007525438A (ja) 2007-09-06
NO20054892D0 (no) 2005-10-21
EP1606316A2 (en) 2005-12-21
AU2004223837C1 (en) 2012-03-15
AU2004223837B2 (en) 2011-04-21
EA200501506A1 (ru) 2006-06-30
EP1606317B1 (en) 2010-07-28
KR20110091598A (ko) 2011-08-11
WO2004085476A3 (en) 2005-03-31
US20100111948A1 (en) 2010-05-06
KR20050116392A (ko) 2005-12-12
AU2004223836A2 (en) 2004-10-07
US20060134756A1 (en) 2006-06-22
MXPA05010134A (es) 2005-11-16
KR20050116390A (ko) 2005-12-12
WO2004085475A3 (en) 2005-07-14
WO2004085475A2 (en) 2004-10-07
US20040209330A1 (en) 2004-10-21
DE602004028347D1 (de) 2010-09-09

Similar Documents

Publication Publication Date Title
NO20054892D0 (no) Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
NO20072602L (no) Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
MXPA06014465A (es) Zcytor14 soluble, anticuerpos anti-zcytor14 y moleculas de union y metodos de uso en inflamacion.
WO2006086396A3 (en) Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2005052000A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
DK1931697T3 (da) IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
WO2008039553A8 (en) Soluble il-17rcx4 and methods of using in inflammation
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
NO20044658L (no) Anvendelse av osteoprotegerin til behandling og/eller forhindring av fibrotiske sykdommer
EA200700823A1 (ru) Растворимый zcytor21, анти-zcytor21 антитела и связывающие партнёры и способы применения при воспалении
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
DE60209797D1 (de) Antikörper zur stimulierung der produktion von il-1ra

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application